Home » Stocks » PBYI

Puma Biotechnology Inc. (PBYI)

Stock Price: $10.33 USD 0.07 (0.63%)
Updated May 18, 2021 1:25 PM EDT - Market open
Market Cap 411.29M
Revenue (ttm) 272.06M
Net Income (ttm) -26.53M
Shares Out 40.36M
EPS (ttm) -0.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 18
Last Price $10.33
Previous Close $10.26
Change ($) 0.07
Change (%) 0.63%
Day's Open 10.27
Day's Range 10.18 - 10.44
Day's Volume 74,153
52-Week Range 7.48 - 14.14

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Puma Biotech (PBYI) beats first-quarter estimates for both earnings and sales. Stock up.

1 week ago - Zacks Investment Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 37.93% and 31.03%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology released its financial results for the first quarter ended March 31, 2021, after market close on May 6, 2021.

1 week ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement awards granted in April 2021 as required under Nasdaq Listing Rule 5635(c)(4) .

1 week ago - Business Wire

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call/webcast at 1:30 p.m. PDT on May 6, 2021, following release of its 1Q-2021 financial results.

3 weeks ago - Business Wire

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Celcuity Inc (NASDAQ: CELC) has announced a clinical trial collaboration with the MD Anderson Cancer Center, Novartis AG (NYSE: NVS), and Puma Biotechnology Inc (NASDAQ: PUMA) to conduct a Phase 2 clini...

Other stocks mentioned: NVS
2 months ago - Benzinga

ALLSCHWIL, Switzerland, March 05, 2021 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) a research driven clinical stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class...

2 months ago - GlobeNewsWire

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO & President, will present an overview of Puma Biotechnology at the virtual Barclays Global Healthcare Conference on March 11, 2021.

2 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present an overview of Puma Biotechnology at H.C. Wainwright's Global Health Care Conf, available online beginning March 9, 2021.

2 months ago - Business Wire

Puma Biotech (PBYI) reports wider-than-expected fourth-quarter loss while sales beat estimates.

2 months ago - Zacks Investment Research

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Returns NERLYNX® Rights in Greater China to Puma Biotechnology as the Two Parties Terminate License Agreement and Settle Arbitration

2 months ago - Business Wire

LOS ANGELES & CASTRES, France--(BUSINESS WIRE)--Puma Biotechnology and Pierre Fabre added Greater China to their license agreement. Puma and CANbridge Pharma terminated their Greater China agreement

2 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology released its financial results for the fourth quarter and year ended Dec. 31, 2020 on Feb. 25, 2020.

2 months ago - Business Wire

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 p.m. PST on February 25 following release of its 4Q-2020 financial results.

3 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement awards for the month of January 2021 as required by Nasdaq Listing Rule 5635(c)(4).

3 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented interim results from the Phase II SUMMIT Trial of Neratinib for EGFR exon 18-mutated, metastatic NSCLC at WCLC 2020.

3 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO and President of Puma Biotechnology, will present a company update at the B. Riley Oncology Investor Conference on Jan. 21.

3 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented interim results from its biliary tract cancers cohort of the Phase II SUMMIT “basket” trial at ASCO GI 2021,

4 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present an overview of Puma Biotechnology at the J.P. Morgan Healthcare Conference on Jan. 14 at 10:50 a.m. EST.

4 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will present a Puma Biotechnology update at H.C. Wainwright's BioConnect VIRTUAL Conference beginning on Jan. 11, 2021 at 6:00 am EST.

4 months ago - Business Wire

Puma Biotechnology continues to report encouraging clinical data for its flagship product, NERLYNX. Unfortunately, the commercial numbers continue to remain in purgatory. I take a look at the company's ...

4 months ago - Seeking Alpha

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported inducement awards for November 2020 as required by Nasdaq Listing Rule 5635(c)(4) .

5 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented efficacy and safety outcomes from the Phase III NALA Trial in a Spotlight Poster at the 2020 Virtual SABCS.

5 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented final overall survival analysis from its Phase III ExteNET Trial at the 2020 San Antonio Breast Cancer Symposium.

5 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented updated results from its Phase II SUMMIT trial in a Spotlight Poster at the 2020 San Antonio Breast Cancer Symposium.

5 months ago - Business Wire

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

LOS ANGELES--(BUSINESS WIRE)--European Patent Office Upholds Puma Biotechnology's Patent Position on EP 1848414 as Granted.

5 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will present 10 posters at the 2020 Virtual San Antonio Breast Cancer Symposium, which will be held Dec. 8-11, 2020.

6 months ago - Business Wire

Puma Biotech (PBYI) falls more than 8% as it misses on both earnings and revenues in the third quarter of 2020. The company trims its 2020 revenue guidance for Nerlynx.

6 months ago - Zacks Investment Research

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported its inducement awards for Oct. 2020 as required by Nasdaq Listing Rule 5635(c)(4).

6 months ago - Business Wire

Puma Biotechnology's (PBYI) CEO Alan Auerbach on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Puma Biotech (PBYI) delivered earnings and revenue surprises of -139.39% and -4.17%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

LOS ANGELES--(BUSINESS WIRE)--On Nov. 5, 2020, Puma Biotechnology released interim results from its Phase II SUMMIT Trial of Neratinib for EGFR Exon 18 mutated, metastatic NSCLC.

6 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--On Nov. 5, 2020, Puma Biotechnology reported its financial results for the third quarter and nine months ended Sept. 30, 2020.

6 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO and President of Puma Biotechnology, will provide a corporate update at the Credit Suisse Virtual Healthcare Conference on Nov. 10

6 months ago - Business Wire

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

LOS ANGELES--(BUSINESS WIRE)--On November 5, 2020, Puma Biotechnology will issue its 3Q-2020 financial results after market close and host a conference call at 1:30 p.m. PST.

6 months ago - Business Wire

PLYMOUTH MEETING, Pa., Oct. 15, 2020 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced plans to evaluate neratinib, a type of tyrosine ki...

7 months ago - PRNewsWire

LOS ANGELES--(BUSINESS WIRE)--Overall survival results from Puma Biotechnology's Phase III ExteNET trial were published online in Clinical Breast Cancer.

7 months ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)--On September 8, 2020, a Court-appointed administrator confirmed the claims of more than 4,600 individual and institutional investors defrauded by Puma Biotechnology and its C...

8 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology CEO Alan Auerbach will provide a company overview at the virtual H.C. Wainwright Global Conference on September 15, 2020.

8 months ago - Business Wire

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock?

8 months ago - Zacks Investment Research

LOS ANGELES--(BUSINESS WIRE)--A manuscript including results from Puma Biotechnology's CONTROL trial was published in the September 2020 issue of Annals of Oncology.

8 months ago - Business Wire

Puma Bio: A Contrarian Investment That Requires Patience

9 months ago - Seeking Alpha

Puma Biotech's (PBYI) bottom and the top line better estimates for the second quarter of 2020.

9 months ago - Zacks Investment Research

Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Puma Biotech (PBYI) delivered earnings and revenue surprises of 130.77% and 26.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

About PBYI

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for... [Read more...]

Industry
Biotechnology
Founded
2010
Stock Exchange
NASDAQ
Ticker Symbol
PBYI
Full Company Profile

Financial Performance

In 2020, PBYI's revenue was $225.11 million, a decrease of -17.32% compared to the previous year's $272.26 million. Losses were -$60.00 million, -20.64% less than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for PBYI stock is "Hold." The 12-month stock price forecast is 10.38, which is an increase of 0.53% from the latest price.

Price Target
$10.38
(0.53% upside)
Analyst Consensus: Hold